ABSTRACT

This thesis research concentrates on the development and applications of mass spectrometry-based metabolomics to elucidate biochemical alterations involved in basic research models for two common human diseases: mammalian cell culture model of hepatocellular carcinoma (HCC) and transgenic mouse model of Alzheimer's disease (AD). Two major approaches were developed: (1) targeted quantitative metabolomics for elucidation of altered cancer metabolism in human liver cell lines caused by the overexpression of the oncogene eukaryotic translation initiation factor 5A2 (EIF5A2) and O-Linked β-N-acetylglucosamine (O-GlcNAc) modification; (2) non-targeted metabolite profiling for early discovery of potential non-invasive urinary metabolite markers in the transgenic mouse model TgCRND8 of AD.

For cancer metabolism research, much effort has been focused on development of ultrahigh performance liquid chromatography triple quadrupole mass spectrometry (UPLC-MS/MS)-based targeted metabolomics method and its emerging applications in exploiting oncogene-induced metabolic alterations. To achieve our goal, more than one hundred intermediate and/or metabolite were selected and broadly categorized into cationic species and anionic species. Tandem mass spectrometric conditions were extensively optimized for each analyte by using energy-resolved collision-induced dissociation. Two crucial operating parameters of tandem mass spectrometry, namely, cone voltage and collision energy were finely tuned to get the highest signal response of the
parent ion and fragment ions. Multiple reaction monitoring (MRM) transitions were created for each targeted compound, providing foundation for MRM-based assays. Meanwhile, to enhance the retention and separation of the water-soluble metabolites on reversed-phase C18 column, hydrophobic ion-pairing interactions separation (HIPS) strategies were proposed and established via complementary use of two ion-pairing reagents, heptafluorobutyric acid and tributylamine, for the cationic species and anionic species, respectively. The ‘HIPS’ strategies led to efficient retention and resolution of polar intermediates/metabolites, covering the majority of components involved in central carbon metabolism and amino acid metabolism. Even isomeric pairs, like citrate-isocitrate and leucine-isoleucine, were almost baseline resolved. The performance evaluation of the developed UPLC MRM-based assays showed that nanomolar levels of limit of quantification were achieved. The developed methods enabled quantitative analysis of central carbon metabolism in mammalian cells. The altered metabolism induced by the overexpression of the oncogene EIF5A2 in human normal liver cell line LO2 was studied. We found that the altered aerobic glycolysis and pentose phosphate pathway dysregulated the tricarboxylic acid (TCA) cycle and amino acid imbalances presented as distinct metabolic features in EIF5A2 overexpressed LO2 cells.

In chapter 3, we performed quantitative analysis of central carbon metabolism and amino acid metabolism via the established UPLC-MRM-based metabolomics, which was combined with pharmacological inhibition of the
catalytic enzymes, O-linked N-acetylglucosamine transferase (O-GlcNAc transferase, OGT) and β-N-acetylglucosaminidase (O-GlcNAcase, OGA) in order to uncover the contribution of protein (including the glycolytic enzymes) O-GlcNAc modification to metabolic alterations in cancer cells. We found that OGA inhibition led to decreased levels of intermediates in both glycolysis and TCA cycle, but increased level of pentose phosphate pathway. Interestingly, the opposite phenotypes were obtained in OGT inhibition, i.e., the increased levels of glycolysis and TCA cycle were observed. Our data suggested that O-GlcNAc modification could direct switches of glucose metabolism through coordinated glycolysis and TCA cycle pathways in HCC cell line.

In chapter 4, an improved UPLC-MS/MS method for accurate and rapid assessment of the content and redox state of coenzyme Q$_{10}$ (CoQ$_{10}$) and the crucial component of electron transport chain (ETC) was described. Non-aqueous reversed phase liquid chromatography on a C18 column was hyphenated with tandem mass spectrometry working in the electrospray ionization positive MRM mode, with methanol serving dual roles as sample preparation solvent and mobile phase. This rapid extractive and analytical method could avoid artificial auto-oxidation of reduced form of CoQ$_{10}$, enabling the native redox state assessment. To demonstrate the utility of the developed method, 2,3,7,8-tetrachlorodibenzo-$_p$-dioxin (TCDD) exposed mice liver tissue were analyzed, revealing the down-regulated mitochondrial ETC in TCDD exposed mice group.
Chapter 5 reported the study to assess whether the urinary metabolic alterations linked to early pathophysiological changes in the TgCRND8 mouse model of AD. An unbiased metabolomics approach using high resolution Orbitrap mass spectrometry coupled with hydrophilic interaction liquid chromatography was conducted to uncover the metabolic alterations as a relevant readout of biochemical activity that implicated in the pathogenesis and progression of AD in the TgCRND8 mice. A total of 73 differential metabolites of urine sample sets was identified in 12-week and 18-week transgenic mice compared to wild-type littermates, covering perturbations of aromatic amino acids metabolism, TCA cycle and one-carbon metabolism. Of particular interest, divergent tryptophan metabolism, such as up-regulation of serotonin pathway while down-regulation of kynurenine pathway, was observed. The accumulation of both N-acetylvanilalanine and 3-methoxytyrosine indicated the aromatic L-amino acid decarboxylase deficiency. The microbial metabolites derived from tryptophan metabolism and drug-like phase II metabolic response via the glycine conjugation reactions were also highlighted, indicating that genetic modification in mouse brain not only alters genotype but also disturbs gut microbiome. Together, our study demonstrated that the integrative approach employing mass spectrometry-based metabolomics and a transgenic mouse model for AD might provide new insights into the metabolic phenotypes of AD with a noninvasive approach.
# Table of Contents

Declaration i

Abstract ii

Acknowledgements vi

Table of contents viii

## Chapter 1 General introduction 1

1.1 Metabolic changes in cancer and Alzheimer’s disease 1

1.2 Mass spectrometry in metabolomics 1

1.2.1 Non-targeted metabolic profiling based on high resolution mass spectrometry 2

1.2.2 Targeted quantitative metabolomics based on triple quadrupole mass spectrometry 19

1.3 Aims of projects 24

## Chapter 2 Development of targeted metabolomics method by using ion-pairing reversed-phase liquid chromatography tandem mass spectrometry to elucidate cancer metabolism 26

2.1 Introduction 26

2.2 Materials and methods 29

2.2.1 Chemicals and reagents 29

2.2.2 Cell culture and sample preparation 30

2.2.3 Instrumentation 31

2.2.4 Quality control using common reference compounds 34

2.2.5 Quantification and method validation 35

2.2.6 Instrument cleaning and maintenance 36
2.3 Results and discussion

2.3.1 Metabolites categorized as cationic or anionic species for complementary separation and detection 36

2.3.2 Fragment ions generated via energy-resolved collision induced dissociation (ER-CID) in QQQ & Q-TOF MS/MS 44

2.3.3 Construction of MRM transition library from ER-CID MS/MS data 51

2.3.4 Hydrophobic ion-pairing interactions (HIPS) separation strategies for targeted metabolomics 51

2.3.5 Performance evaluation of the developed method 56

2.3.6 Application to elucidate altered cancer metabolism 60

2.4 Chapter summary 65

Chapter 3 Coordinated alterations of glucose metabolism modulated by the O-GlcNAcylation in HCC cell line 66

3.1 Introduction 66

3.2 Materials and methods 68

3.2.1 Chemicals and reagents 68

3.2.2 Cell culture and sample preparation 68

3.3. Instrumentation 69

3.4 Quantification and method validation 70

3.5 Results and discussion 71

3.5.1 OGA inhibition induced metabolic alterations 71

3.5.2 OGT inhibition induced metabolic alterations 75

3.6 Chapter summary 79
## Chapter 4 Rapid assessment of coenzyme Q₁₀ redox state by using ultrahigh performance liquid chromatography tandem mass spectrometry

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.1 Introduction</td>
<td>80</td>
</tr>
<tr>
<td>4.2 Materials and methods</td>
<td>82</td>
</tr>
<tr>
<td>4.2.1 Chemicals and reagents</td>
<td>82</td>
</tr>
<tr>
<td>4.2.2 Instrumentation and UPLC-MS/MS analysis</td>
<td>83</td>
</tr>
<tr>
<td>4.2.3 Animal experiment</td>
<td>83</td>
</tr>
<tr>
<td>4.2.4 Standard solution preparation</td>
<td>84</td>
</tr>
<tr>
<td>4.2.5 Tissue sample pre-treatment and CoQ₁₀ extraction</td>
<td>85</td>
</tr>
<tr>
<td>4.2.6 Method validation</td>
<td>85</td>
</tr>
<tr>
<td>4.3 Results and discussion</td>
<td>86</td>
</tr>
<tr>
<td>4.3.1 UPLC–ESI-MS/MS method development</td>
<td>86</td>
</tr>
<tr>
<td>4.3.2 Coenzyme Q₁₀ extraction optimization</td>
<td>91</td>
</tr>
<tr>
<td>4.3.3 Method validation</td>
<td>93</td>
</tr>
<tr>
<td>4.3.4 Biological application</td>
<td>96</td>
</tr>
<tr>
<td>4.4 Chapter summary</td>
<td>98</td>
</tr>
</tbody>
</table>

## Chapter 5 Non-targeted metabolomics for the study on urinary alterations of Alzheimer’s disease in the CRND8 transgenic mice

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.1 Introduction</td>
<td>99</td>
</tr>
<tr>
<td>5.2 Materials and methods</td>
<td>101</td>
</tr>
<tr>
<td>5.2.1 Animals and experimental design</td>
<td>101</td>
</tr>
<tr>
<td>5.2.2 HILIC LTQ-Orbitrap MS analysis</td>
<td>104</td>
</tr>
<tr>
<td>5.2.3 Raw data processing</td>
<td>105</td>
</tr>
</tbody>
</table>
5.2.4 Multivariate statistical analysis ........................................ 106
5.2.5 Metabolites annotation and pathway analysis ................. 106

5.3 Results ........................................................................ 107
5.3.1 Metabolic alteration and distinct metabolite excretion pattern of TgCRND8 mice ......................................................... 107
5.3.2 Systemic perturbations of urinary metabolomes in 12-week and 18-week TgCRND8 mice .................................................... 110
5.3.3 Age-related changes in urinary metabolites of TgCRND8 mice from 12-week to 18-week .................................................. 116

5.4 Discussion .................................................................. 119
5.4.1 Distinctive features of aromatic amino acid catabolism in TgCRND8 mice ................................................................. 119
5.4.2 Elevated urinary α-ketoglutarate along with diminished thiamine in TgCRND8 mice: Disturbed mitochondrial energy metabolism ................................................. 123
5.4.3 Altered one-carbon cycle metabolism in TgCRND8 mice: Evidence linking increased oxidative stress and mitochondrial dysfunction .............................................. 124

5.5 Chapter summary .......................................................... 125

Chapter 6 Conclusions and Future Studies .............................. 127

References ........................................................................ 130

Appendix ............................................................................. 165

Appendix for Chapter 2 .......................................................... 165

Table A2.1 List of commercially available chemicals used as the targeted metabolite references or internal standards in this work ............... 165

Appendix for Chapter 4 ............................................................ 168

Table A4.1 Within- and between-day assay variability ............... 168

Figure A4.1 Sample carryover test ........................................... 169
Appendix for Chapter 5

File A5.1 XCMS detailed parameters used for metabolomics data pretreatment, taking 12W dataset positive ion mode data as an example 171

Figure A5.2 PCA scores plots of metabolomic comparison between TgCRND8 mice and the age-matched non-Tg controls 172

Figure A5.3 OPLS-DA scores plots of metabolomic comparison between TgCRND8 mice and the age-matched non-Tg controls 173

Figure A5.4 Supervised partial least squares discriminant analysis (PLS-DA) of the urine samples from TgCRND8 mice and age-matched controls at age of 18-weeks-old 174

Figure A5.5 Schematic diagram for parallel-sequential analysis 175

Figure A5.6 No separation could be seen between the non-Tg controls at different ages as shown in the PCA scores plots (18W Non-Tg Vs 12W Non-Tg) 176

Table A5.1 Differentiating metabolites between TgCRND8 mice and age-matched controls identified from the 18W Dataset (Tg/Non-Tg) 177

Curriculum Vitae 181